Artiva Biotherapeutics’ (ARTV) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a research report released on Wednesday,Benzinga reports. The firm currently has a $20.00 price target on the stock. HC Wainwright also issued estimates for Artiva Biotherapeutics’ Q1 2025 earnings at ($0.68) EPS, Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($2.89) EPS, FY2026 earnings at ($3.44) EPS and FY2027 earnings at ($4.10) EPS.

Other research analysts have also recently issued reports about the company. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a research report on Tuesday. Cantor Fitzgerald lowered their price target on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Tuesday. Finally, Wedbush reiterated an “outperform” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research report on Tuesday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $20.40.

Artiva Biotherapeutics Stock Performance

Artiva Biotherapeutics stock opened at $3.16 on Wednesday. Artiva Biotherapeutics has a 52-week low of $3.15 and a 52-week high of $17.31. The business has a 50-day simple moving average of $4.71 and a two-hundred day simple moving average of $9.23.

Institutional Trading of Artiva Biotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. purchased a new stake in Artiva Biotherapeutics in the third quarter worth about $623,000. BNP Paribas Financial Markets bought a new position in shares of Artiva Biotherapeutics during the third quarter valued at approximately $42,000. MetLife Investment Management LLC purchased a new position in Artiva Biotherapeutics during the third quarter valued at approximately $135,000. Acuta Capital Partners LLC bought a new position in Artiva Biotherapeutics in the third quarter worth approximately $680,000. Finally, RTW Investments LP purchased a new stake in Artiva Biotherapeutics during the third quarter worth $2,300,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.